Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer

NCT01187212 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT01187212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01187212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
August 31, 2014
Enrollment
195 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effects of chemotherapy, malignant neoplasm of stomach